Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China’s National Reimbursement Drug List
Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and...

